Action FOAMIX PHARMACEUTICALS LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Foamix Pharmaceuticals Ltd. Nasdaq

Actions

IL0011334385

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Value Index
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer
Arvinas, Inc. Appoints Andrew Saik as Treasurer
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
Top Premarket Gainers
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VYNE
  4. Action
  5. Actualités Foamix Pharmaceuticals Ltd.
  6. Autres langues